Autoantibodies targeting G protein-coupled receptors: An evolving history in autoimmunity. Report of the 4th international symposium.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cabral-Marques Otávio, Moll Guido, Catar Rusan, Preuß Beate, Bankamp Lukas, Pecher Ann-Christin, Henes Joerg, Klein Reinhild, Kamalanathan A S, Akbarzadeh Reza, van Oostveen Wieke, Hohberger Bettina, Endres Matthias, Koolmoes Bryan, Levarht Nivine, Postma Rudmer, van Duinen Vincent, van Zonneveld Anton Jan, de Vries-Bouwstra Jeska, Fehres Cynthia, Tran Florian, do Vale Fernando Yuri Nery, da Silva Souza Kamilla Batista, Filgueiras Igor Salerno, Schimke Lena F, Baiocchi Gabriela Crispim, de Miranda Gustavo Cabral, da Fonseca Dennyson Leandro Mathias, Freire Paula Paccielli, Hackel Alexander M, Grasshoff Hanna, Stähle Anja, Müller Antje, Dechend Ralf, Yu Xinhua, Petersen Frank, Sotzny Franziska, Sakmar Thomas P, Ochs Hans D, Schulze-Forster Kai, Heidecke Harald, Scheibenbogen Carmen, Shoenfeld Yehuda, Riemekasten Gabriela
Аннотация
G protein-coupled receptors (GPCR) are involved in various physiological and pathophysiological processes. Functional autoantibodies targeting GPCRs have been associated with multiple disease manifestations in this context. Here we summarize and discuss the relevant findings and concepts presented in the biennial International Meeting on autoantibodies targeting GPCRs (the 4th Symposium), held in Lübeck, Germany, 15-16 September 2022. The symposium focused on the current knowledge of these autoantibodies' role in various diseases, such as cardiovascular, renal, infectious (COVID-19), and autoimmune diseases (e.g., systemic sclerosis and systemic lupus erythematosus). Beyond their association with disease phenotypes, intense research related to the mechanistic action of these autoantibodies on immune regulation and pathogenesis has been developed, underscoring the role of autoantibodies targeting GPCRs on disease outcomes and etiopathogenesis. The observation repeatedly highlighted that autoantibodies targeting GPCRs could also be present in healthy individuals, suggesting that anti-GPCR autoantibodies play a physiologic role in modeling the course of diseases. Since numerous therapies targeting GPCRs have been developed, including small molecules and monoclonal antibodies designed for treating cancer, infections, metabolic disorders, or inflammatory conditions, anti-GPCR autoantibodies themselves can serve as therapeutic targets to reduce patients' morbidity and mortality, representing a new area for the development of novel therapeutic interventions.